Harvest Capital
VC Fund
Concord, United States
Harvest Capital is a VC fund in Concord focused on Medical and Life Science. Harvest Capital specializes in wealth and investment management services, business transition planning, and for those who have achieved significant wealth, they offer family office services. They are a privately-owned firm that believes in promoting family continuity, educating family members about financial matters, and managing the “business ofthe family,” while protecting and growing assets.They help people attain life goals, as well as financial objectives – while maintaining a sustained, comfortable lifestyle for you and your loved ones.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Harvest Capital invests in
Stages Harvest Capital invests in
Countries Harvest Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brian Presti
|
|||
Diane Chadwick
|
|||
James Fitts
|
|||
Marshall Rowe
|
|||
|
Pan Teng
|
Investment Focus
Industry
- Medical 4 (40%)
- Life Science 4 (40%)
- Biotechnology 4 (40%)
- Health Care 3 (30%)
- Retail 1 (10%)
Stage
- Series B 3 (30%)
- Series C 2 (20%)
- Seed 1 (10%)
- Series A 1 (10%)
- Series D 1 (10%)
Country
- China 8 (80%)
- Taiwan 1 (10%)
- United States 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Brian Presti
Chief Investment Officer
|
Chief Investment Officer | Total investments: 0 | Find email | |
|
Diane Chadwick
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
|
James Fitts
Managing Director & Chief Planning Officer
|
Managing Director & Chief Planning Officer | Total investments: 0 | Find email | |
|
Marshall Rowe
President & Chief Executive Officer
|
President & Chief Executive Officer | Total investments: 0 | Find email | |
|
Pan Teng
Partner
|
Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Small Vegetable Garden
|
Xiaocaiyuan is the operator of a chain of restaurants. It offers customers green, healthy, and nourishing dishes. They provide customers with the opportunity to experience Anhui cuisine that combines tradition and innovation. | $70.6M / Venture - Series Unknown / Dec 19, 2023 | |
BiomeSense
|
BiomeSense is developing the first technology platform for continuous, at-home monitoring of the human gut microbiome, transforming the ability to understand & utilize the microbiome for precision medicine. The enabling technology is the GutLab, the first “smart bathroom” system for at-home microbiome monitoring, which is combined with theMetaBiome time-series analytics platform into a single end-to-end solution. The platform allows scientists, patients, and consumers the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, revolutionizing the ability to leverage the microbiome for better health. | $3M / Seed / Feb 05, 2023 | |
Qinghai Lihao
|
Qinghai Lihao engages in the process technology research and development, production, sales and related supporting new energy business. | $306.5M / Series B / Sep 27, 2022 | |
APRINOIA Therapeutics
|
APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau,alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston. | $40M / Series C / Dec 28, 2021 | |
Gene+
|
Beijing Gene+, also known as Beijing Gene Plus, provides gene testing services for cancer prevention, early detection, as well as providing data for the implementation of precision medicine. The company claims to operate in around 100 hospitals and have served thousands of cancer patients in China. | $115.9M / Series C / Jul 22, 2021 | |
Neurophth Therapeutics
|
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally. | $61.9M / Series B / Feb 09, 2021 | |
Pinpianyi
|
Pinpianyi is a Hangzhou-based start-up developing smart procurement platform for convenience stores, helping them minimize procurement cost and logistics cost. So far it has provided services for over 10,000 offline stores, connecting with more than 1,000 suppliers. | Series A / Jun 20, 2018 | |
Hua Medicine
|
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXiVentures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action. | $117.4M / Series D / Mar 27, 2018 | |
Easyhome Furnishing New Retail Chain Store Group
|
Easyhome Furnishing New Retail Chain Store Group is a retail business. | $1.8B / Private Equity / Feb 11, 2018 | |
Channelsoft (Beijing) Technology
|
ChannelSoft (Beijing) Technologies Co., Ltd. (“ChannelSoft“) is a leading provider of communications software products and services in Mainland China, dedicated to the research and development of technologies and products for the converging networks of communications, computer and cable TV. It ranks first in the domestic market of telecomvalue-added service platforms and call center platforms. | Series B / Mar 30, 2017 |
Co-Investors
SOSV
3 deals together
InnoVision Capital
2 deals together
51 Credit Card Manager
1 deal together
6 Dimensions Capital
1 deal together
Alibaba Group
1 deal together
Alibaba Health Information Technology
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Harvest Capital invest in?
Harvest Capital invests primarily in Medical, Life Science and Biotechnology startups, most often at Series B and Series C stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Harvest Capital?
Public channels for Harvest Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Harvest Capital?
The team at Harvest Capital includes Brian Presti (Chief Investment Officer), Diane Chadwick (Chief Operating Officer) and James Fitts (Managing Director & Chief Planning Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
